Introduction
============

This issue includes an interesting article by Sternberg et al. showing that the flavonoid luteolin inhibits IL-1, TNF and metalloproteinase-9 (MMP-9) release from activated peripheral blood mononuclear cells (PBMCs) from multiple sclerosis (MS) patients, and that the effect of luteolin is augmented by concurrent administration of interferon-beta (IFN-β). This paper extends previous similar results with quercetin that required higher concentrations of the flavonoid \[[@B1]\].

Discussion
==========

Luteolin with or without IFN-β, could be helpful in MS by not only inhibiting PBMC release of cytokines, but also by inhibiting T cells, which we recently showed can be superstimulated by mast cells, an action also inhibited by luteolin \[[@B2]\]. In addition to T cells, recent evidence implicates also TH2 processes typically associated with allergic reactions \[[@B3]-[@B5]\], which involve mast cells (Fig. [1](#F1){ref-type="fig"}). In fact, mast cells have been considered as the next target for MS therapy \[[@B6]-[@B8]\].

![**Diagrammatic representation of the inhibitory effect of luteolin on brain mast cells and infiltrating monocytes in the pathogenesis of multiple sclerosis**.](1742-2094-6-29-1){#F1}

Brain MS plaques also contain activated mast cells \[[@B9],[@B10]\], which have been associated with brain demyelination \[[@B11]-[@B13]\]. Gene array analysis also showed that MS plaques had increased gene expression for the IgE receptor (FcεRI), the histamine-1 receptor and the protease tryptase, all of which are associated with mast cells \[[@B14]-[@B16]\]. Mast cell tryptase is elevated in the CSF of MS patients \[[@B17]\], can activate peripheral mononuclear cells to secrete TNF and IL-6 \[[@B18]\], as well as stimulate protease-activated receptors (PAR) to induce widespread inflammation \[[@B19]\]. Brain mast cells can secrete TNF \[[@B20]\], which is involved in both brain inflammation \[[@B21]\] and blood-brain-barrier (BBB) permeability \[[@B22]\]. In fact, BBB disruption precedes any pathologic signs of MS \[[@B23]\] and mast cells can disrupt the BBB \[[@B24],[@B25]\].

Flavonoids such as quercetin have potent anti-oxidant and anti-inflammatory activity \[[@B26]\]. Quercetin and luteolin also inhibit human cultured mast cell release of histamine, leukotrienes and prostaglandin D~2~\[[@B27]\], as well as IL-6, IL-8, TNF-α and tryptase \[[@B28],[@B29]\]. Moreover, quercetin and luteolin inhibit mast cell activation stimulated by IL-1 \[[@B30]\] leading to selective release of IL-6. Luteolin also inhibits IL-6 release from microglia cells \[[@B31]\], and from astrocytes \[[@B32]\]. Flavonoids can also inhibit myelin phagocytosis by macrophages \[[@B33]\], as well as inhibit EAE \[[@B34]-[@B36]\].

Conclusion
==========

Quercetin and its structurally related luteolin are safe \[[@B37]\]. The fact remains that less than 10% of flavonoids are absorbed orally \[[@B37]\]. Novel ways of delivering select flavonoid combinations would be required to assure sufficient plasma levels, especially if luteolin were to also inhibit brain inflammation. Such a test nutraceutical formulation has already been tried on a number of relapsing-remitting MS patients treated with INF-β with encouraging positive results.
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